New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer

NEXT STORY
Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer
PREV STORY
Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community

NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a ...

author_avatar
NASDAQ Market News

CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States

— Kowa to fully fund development through NDA approval— CymaBay to receive up to ...

author_avatar
NASDAQ Market News

Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial

LOS ANGELES, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter ...

author_avatar
NASDAQ Market News